Copyright Reports & Markets. All rights reserved.

Global Breakthrough Therapy (BT) Designation Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Breakthrough Therapy (BT) Designation Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Breakthrough Therapy (BT) Designation Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Oncology
    • 1.4.3 Infectious Diseases
    • 1.4.4 Rare Diseases
    • 1.4.5 Autoimmune Diseases
    • 1.4.6 Pulmonary Diseases
    • 1.4.7 Neurological Disorders
    • 1.4.8 Others
  • 1.5 Market by Application
    • 1.5.1 Global Breakthrough Therapy (BT) Designation Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Research Institute
    • 1.5.5 Laboratories
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Breakthrough Therapy (BT) Designation Market Perspective (2015-2026)
  • 2.2 Global Breakthrough Therapy (BT) Designation Growth Trends by Regions
    • 2.2.1 Breakthrough Therapy (BT) Designation Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Breakthrough Therapy (BT) Designation Historic Market Share by Regions (2015-2020)
    • 2.2.3 Breakthrough Therapy (BT) Designation Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Breakthrough Therapy (BT) Designation Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Breakthrough Therapy (BT) Designation Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Breakthrough Therapy (BT) Designation Players by Market Size
    • 3.1.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue (2015-2020)
    • 3.1.2 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Breakthrough Therapy (BT) Designation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio
    • 3.2.1 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Breakthrough Therapy (BT) Designation Revenue in 2019
  • 3.3 Breakthrough Therapy (BT) Designation Key Players Head office and Area Served
  • 3.4 Key Players Breakthrough Therapy (BT) Designation Product Solution and Service
  • 3.5 Date of Enter into Breakthrough Therapy (BT) Designation Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Type (2015-2020)
  • 4.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Breakthrough Therapy (BT) Designation Market Size by Application (2015-2020)
  • 5.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Breakthrough Therapy (BT) Designation Market Size (2015-2020)
  • 6.2 Breakthrough Therapy (BT) Designation Key Players in North America (2019-2020)
  • 6.3 North America Breakthrough Therapy (BT) Designation Market Size by Type (2015-2020)
  • 6.4 North America Breakthrough Therapy (BT) Designation Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Breakthrough Therapy (BT) Designation Market Size (2015-2020)
  • 7.2 Breakthrough Therapy (BT) Designation Key Players in Europe (2019-2020)
  • 7.3 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2015-2020)
  • 7.4 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2015-2020)

8 China

  • 8.1 China Breakthrough Therapy (BT) Designation Market Size (2015-2020)
  • 8.2 Breakthrough Therapy (BT) Designation Key Players in China (2019-2020)
  • 8.3 China Breakthrough Therapy (BT) Designation Market Size by Type (2015-2020)
  • 8.4 China Breakthrough Therapy (BT) Designation Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Breakthrough Therapy (BT) Designation Market Size (2015-2020)
  • 9.2 Breakthrough Therapy (BT) Designation Key Players in Japan (2019-2020)
  • 9.3 Japan Breakthrough Therapy (BT) Designation Market Size by Type (2015-2020)
  • 9.4 Japan Breakthrough Therapy (BT) Designation Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Breakthrough Therapy (BT) Designation Market Size (2015-2020)
  • 10.2 Breakthrough Therapy (BT) Designation Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Breakthrough Therapy (BT) Designation Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Breakthrough Therapy (BT) Designation Market Size by Application (2015-2020)

11 India

  • 11.1 India Breakthrough Therapy (BT) Designation Market Size (2015-2020)
  • 11.2 Breakthrough Therapy (BT) Designation Key Players in India (2019-2020)
  • 11.3 India Breakthrough Therapy (BT) Designation Market Size by Type (2015-2020)
  • 11.4 India Breakthrough Therapy (BT) Designation Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Breakthrough Therapy (BT) Designation Market Size (2015-2020)
  • 12.2 Breakthrough Therapy (BT) Designation Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Breakthrough Therapy (BT) Designation Market Size by Type (2015-2020)
  • 12.4 Central & South America Breakthrough Therapy (BT) Designation Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Roche
    • 13.1.1 Roche Company Details
    • 13.1.2 Roche Business Overview
    • 13.1.3 Roche Breakthrough Therapy (BT) Designation Introduction
    • 13.1.4 Roche Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020))
    • 13.1.5 Roche Recent Development
  • 13.2 Abbvie
    • 13.2.1 Abbvie Company Details
    • 13.2.2 Abbvie Business Overview
    • 13.2.3 Abbvie Breakthrough Therapy (BT) Designation Introduction
    • 13.2.4 Abbvie Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.2.5 Abbvie Recent Development
  • 13.3 Novartis International AG
    • 13.3.1 Novartis International AG Company Details
    • 13.3.2 Novartis International AG Business Overview
    • 13.3.3 Novartis International AG Breakthrough Therapy (BT) Designation Introduction
    • 13.3.4 Novartis International AG Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.3.5 Novartis International AG Recent Development
  • 13.4 Janssen
    • 13.4.1 Janssen Company Details
    • 13.4.2 Janssen Business Overview
    • 13.4.3 Janssen Breakthrough Therapy (BT) Designation Introduction
    • 13.4.4 Janssen Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.4.5 Janssen Recent Development
  • 13.5 BMS
    • 13.5.1 BMS Company Details
    • 13.5.2 BMS Business Overview
    • 13.5.3 BMS Breakthrough Therapy (BT) Designation Introduction
    • 13.5.4 BMS Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.5.5 BMS Recent Development
  • 13.6 Eli Lilly
    • 13.6.1 Eli Lilly Company Details
    • 13.6.2 Eli Lilly Business Overview
    • 13.6.3 Eli Lilly Breakthrough Therapy (BT) Designation Introduction
    • 13.6.4 Eli Lilly Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.6.5 Eli Lilly Recent Development
  • 13.7 Gilead
    • 13.7.1 Gilead Company Details
    • 13.7.2 Gilead Business Overview
    • 13.7.3 Gilead Breakthrough Therapy (BT) Designation Introduction
    • 13.7.4 Gilead Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.7.5 Gilead Recent Development
  • 13.8 Sanofi
    • 13.8.1 Sanofi Company Details
    • 13.8.2 Sanofi Business Overview
    • 13.8.3 Sanofi Breakthrough Therapy (BT) Designation Introduction
    • 13.8.4 Sanofi Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.8.5 Sanofi Recent Development
  • 13.9 Regeneron
    • 13.9.1 Regeneron Company Details
    • 13.9.2 Regeneron Business Overview
    • 13.9.3 Regeneron Breakthrough Therapy (BT) Designation Introduction
    • 13.9.4 Regeneron Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.9.5 Regeneron Recent Development
  • 13.10 Acadia
    • 13.10.1 Acadia Company Details
    • 13.10.2 Acadia Business Overview
    • 13.10.3 Acadia Breakthrough Therapy (BT) Designation Introduction
    • 13.10.4 Acadia Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 13.10.5 Acadia Recent Development
  • 13.11 Boehringer Ingelheim
    • 10.11.1 Boehringer Ingelheim Company Details
    • 10.11.2 Boehringer Ingelheim Business Overview
    • 10.11.3 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Introduction
    • 10.11.4 Boehringer Ingelheim Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.11.5 Boehringer Ingelheim Recent Development
  • 13.12 Amgen
    • 10.12.1 Amgen Company Details
    • 10.12.2 Amgen Business Overview
    • 10.12.3 Amgen Breakthrough Therapy (BT) Designation Introduction
    • 10.12.4 Amgen Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.12.5 Amgen Recent Development
  • 13.13 AstraZeneca
    • 10.13.1 AstraZeneca Company Details
    • 10.13.2 AstraZeneca Business Overview
    • 10.13.3 AstraZeneca Breakthrough Therapy (BT) Designation Introduction
    • 10.13.4 AstraZeneca Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.13.5 AstraZeneca Recent Development
  • 13.14 GlaxoSmithKline
    • 10.14.1 GlaxoSmithKline Company Details
    • 10.14.2 GlaxoSmithKline Business Overview
    • 10.14.3 GlaxoSmithKline Breakthrough Therapy (BT) Designation Introduction
    • 10.14.4 GlaxoSmithKline Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.14.5 GlaxoSmithKline Recent Development
  • 13.15 Vertex
    • 10.15.1 Vertex Company Details
    • 10.15.2 Vertex Business Overview
    • 10.15.3 Vertex Breakthrough Therapy (BT) Designation Introduction
    • 10.15.4 Vertex Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.15.5 Vertex Recent Development
  • 13.16 Alexion
    • 10.16.1 Alexion Company Details
    • 10.16.2 Alexion Business Overview
    • 10.16.3 Alexion Breakthrough Therapy (BT) Designation Introduction
    • 10.16.4 Alexion Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.16.5 Alexion Recent Development
  • 13.17 Merck
    • 10.17.1 Merck Company Details
    • 10.17.2 Merck Business Overview
    • 10.17.3 Merck Breakthrough Therapy (BT) Designation Introduction
    • 10.17.4 Merck Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.17.5 Merck Recent Development
  • 13.18 Jazz Pharmaceuticals
    • 10.18.1 Jazz Pharmaceuticals Company Details
    • 10.18.2 Jazz Pharmaceuticals Business Overview
    • 10.18.3 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Introduction
    • 10.18.4 Jazz Pharmaceuticals Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.18.5 Jazz Pharmaceuticals Recent Development
  • 13.19 Exelixis
    • 10.19.1 Exelixis Company Details
    • 10.19.2 Exelixis Business Overview
    • 10.19.3 Exelixis Breakthrough Therapy (BT) Designation Introduction
    • 10.19.4 Exelixis Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.19.5 Exelixis Recent Development
  • 13.20 Eisai
    • 10.20.1 Eisai Company Details
    • 10.20.2 Eisai Business Overview
    • 10.20.3 Eisai Breakthrough Therapy (BT) Designation Introduction
    • 10.20.4 Eisai Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.20.5 Eisai Recent Development
  • 13.21 Takeda
    • 10.21.1 Takeda Company Details
    • 10.21.2 Takeda Business Overview
    • 10.21.3 Takeda Breakthrough Therapy (BT) Designation Introduction
    • 10.21.4 Takeda Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.21.5 Takeda Recent Development
  • 13.22 Pfizer
    • 10.22.1 Pfizer Company Details
    • 10.22.2 Pfizer Business Overview
    • 10.22.3 Pfizer Breakthrough Therapy (BT) Designation Introduction
    • 10.22.4 Pfizer Revenue in Breakthrough Therapy (BT) Designation Business (2015-2020)
    • 10.22.5 Pfizer Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Breakthrough Therapy (BT) Designation market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Breakthrough Therapy (BT) Designation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Roche
    Abbvie
    Novartis International AG
    Janssen
    BMS
    Eli Lilly
    Gilead
    Sanofi
    Regeneron
    Acadia
    Boehringer Ingelheim
    Amgen
    AstraZeneca
    GlaxoSmithKline
    Vertex
    Alexion
    Merck
    Jazz Pharmaceuticals
    Exelixis
    Eisai
    Takeda
    Pfizer

    Market segment by Type, the product can be split into
    Oncology
    Infectious Diseases
    Rare Diseases
    Autoimmune Diseases
    Pulmonary Diseases
    Neurological Disorders
    Others
    Market segment by Application, split into
    Hospital
    Clinic
    Research Institute
    Laboratories

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now